



**BIOLEX, INC. ANNOUNCES APPOINTMENT OF  
NEW VICE PRESIDENT OF RESEARCH AND DEVELOPMENT AND  
CHIEF OPERATING OFFICER**

**PITTSBORO, NC, OCT 29, 2001** - Biolex, Inc., a company with proprietary plant-based recombinant protein development and manufacturing technology, announced today the appointment of David G. Spencer, Ph.D. as the company's new Vice-President of Research and Development and Chief Operating Officer. Dr. Spencer was previously Vice President, Respiratory and Critical Care Life Cycle Management, Biological Products Business Unit, Bayer Corporation, Pharmaceutical Division in Raleigh, NC.

"We are delighted to have David join our management team," said Jan P. Turek, President and Chief Executive Officer of Biolex, Inc. "With over 18 years of global, broad-based experience in the industry, and particular expertise in R & D and Operations, he will have an important role at Biolex as we continue to meet our milestones, and scaleup and further develop our manufacturing facilities."

Dr. Spencer comes to Biolex, Inc. with a unique blend of pharmaceutical and biotechnology expertise. Most recently, he had worldwide responsibility for marketed and pipeline products in the Respiratory and Critical Care business franchises of the Biological Products Business Unit of Bayer Corporation in Research Triangle Park, NC . In addition to marketing and development responsibilities, that position required a deep understanding of protein purification and production. In addition, he was also responsible for worldwide operational clinical development for all business franchises of that Business Unit. Prior to this post, Dr. Spencer was Vice President, International Strategic Marketing for Biological Products Business Unit at Bayer.

more ...





**BIOLEX, INC. ANNOUNCES APPOINTMENT OF  
NEW VICE PRESIDENT OF RESEARCH AND DEVELOPMENT AND  
CHIEF OPERATING OFFICER**

Earlier in his career, Dr. Spencer spent 11 years working for the Pharmaceutical Division of Bayer AG in Europe in various international leadership positions. His activities there began in 1983 in research, with drug discovery efforts in the therapeutic areas of anxiety, depression and senile dementia. In 1987, Dr. Spencer began a 5-year period as Project Manager, supervising the international development team of a promising new anxiolytic/antidepressant. During that time, the project advanced through a range of clinical development and regulatory stages. In 1991, Dr. Spencer moved to new business development in International Strategic Marketing, where he developed new techniques for marketing evaluation of pipeline products in the cardiovascular business franchise.

Dr. Spencer received his B.A. in Psychobiology at The University of California at Los Angeles (UCLA), an M.A. in Physiological Psychology at California State University at Fullerton, CA and a Ph.D. in Physiological Psychology at Indiana University in Bloomington, IN. He has published extensively in his field of research and has held several distinctions including Board Member for the Consortium for Plasma Sciences and Consultant to the Bayer Bioethics Advisory Council.

Biolex, Inc. is a biotechnology company devoted to discovering, developing and commercializing proteins derived from proprietary plant-based technology for the development of human therapeutics, and other biotechnology applications. The company's headquarters and laboratory facility are based in Pittsboro, N.C., strategically located near Research Triangle Park. Visit the company's web site at [www.biolex.com](http://www.biolex.com)

CONTACT: Jan P. Turek, President and CEO, Biolex, Inc. 919-542-9901 or Lisa A. Wilder, President, Wilder Communications, Inc., 919-349-3357

###



158 Credle Street  
Pittsboro, NC 27312  
[www.biolex.com](http://www.biolex.com)

tel 919.542.9901  
fax 919.542.9910